X0508 4 2024-10-17 0001885522 Neumora Therapeutics, Inc. NMRA 0001397266 Fust Matthew K C/O NEUMORA THERAPEUTICS, INC. 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 true true Common Stock 2024-10-17 4 M 0 3783 8.32 A 23883 D Common Stock 2024-10-17 4 M 0 1800 8.79 A 25683 D Common Stock 2024-10-17 4 M 0 2156 2.52 A 27839 D Common Stock 2024-10-17 4 S 0 7739 17.0103 D 20100 D Common Stock 2024-10-18 4 M 0 6205 8.79 A 26305 D Common Stock 2024-10-18 4 M 0 7844 2.52 A 34149 D Common Stock 2024-10-18 4 S 0 14049 17.0346 D 20100 D Stock Option (Right to Buy) 8.32 2024-10-17 4 M 0 3783 0 D 2030-09-07 Common Stock 3783 0 D Stock Option (Right to Buy) 8.79 2024-10-17 4 M 0 1800 0 D 2030-09-07 Common Stock 1800 6205 D Stock Option (Right to Buy) 2.52 2024-10-17 4 M 0 2156 0 D 2031-04-22 Common Stock 2156 93430 D Stock Option (Right to Buy) 8.79 2024-10-18 4 M 0 6205 0 D 2030-09-07 Common Stock 6205 0 D Stock Option (Right to Buy) 2.52 2024-10-18 4 M 0 7844 0 D 2031-04-22 Common Stock 7844 85586 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024. This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares subject to the option are fully vested and exercisable. /s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust 2024-10-18